Mass spectrometry-based biomarkers to detect prostate cancer: a multicentric study based on non-invasive urine collection without prior digital rectal examination

Frantzi, M. et al. (2023) Mass spectrometry-based biomarkers to detect prostate cancer: a multicentric study based on non-invasive urine collection without prior digital rectal examination. Cancers, 15(4), 1166. (doi: 10.3390/cancers15041166) (PMID:36831508) (PMCID:PMC9954607)

[img] Text
292563.pdf - Published Version
Available under License Creative Commons Attribution.

6MB

Abstract

(1) Background: Prostate cancer (PCa) is the most frequently diagnosed cancer in men. Wide application of prostate specific antigen test has historically led to over-treatment, starting from excessive biopsies. Risk calculators based on molecular and clinical variables can be of value to determine the risk of PCa and as such, reduce unnecessary and invasive biopsies. Urinary molecular studies have been mostly focusing on sampling after initial intervention (digital rectal examination and/or prostate massage). (2) Methods: Building on previous proteomics studies, in this manuscript, we aimed at developing a biomarker model for PCa detection based on urine sampling without prior intervention. Capillary electrophoresis coupled to mass spectrometry was applied to acquire proteomics profiles from 970 patients from two different clinical centers. (3) Results: A case-control comparison was performed in a training set of 413 patients and 181 significant peptides were subsequently combined by a support vector machine algorithm. Independent validation was initially performed in 272 negative for PCa and 138 biopsy-confirmed PCa, resulting in an AUC of 0.81, outperforming current standards, while a second validation phase included 147 PCa patients. (4) Conclusions: This multi-dimensional biomarker model holds promise to improve the current diagnosis of PCa, by guiding invasive biopsies.

Item Type:Articles
Additional Information:This work was supported in part by the BioGuidePCa (E! 11023, Eurostars) funded by BMBF (Germany), and partly by Spanish grant ICSIII and the European Social Funds (FSE) (PI22/01769).
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Mischak, Professor Harald
Creator Roles:
Mischak, H.Conceptualization, Investigation, Resources, Writing – review and editing, Supervision, Funding acquisition
Authors: Frantzi, M., Culig, Z., Heidegger, I., Mokou, M., Latosinska, A., Roesch, M. C., Merseburger, A. S., Makridakis, M., Vlahou, A., Blanca-Pedregosa, A., Carrasco-Valiente, J., Mischak, H., and Gomez-Gomez, E.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:Cancers
Publisher:MDPI
ISSN:2072-6694
ISSN (Online):2072-6694
Published Online:11 February 2023
Copyright Holders:Copyright © 2023 The Authors
First Published:First published in Cancers 15(4): 1166
Publisher Policy:Reproduced under a Creative Commons License
Data DOI:10.5281/zenodo.7583241

University Staff: Request a correction | Enlighten Editors: Update this record